{"name":"BioAtla, Inc.","slug":"bioatla-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BA3071","genericName":"BA3071","slug":"ba3071","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CAB-AXL-ADC","genericName":"CAB-AXL-ADC","slug":"cab-axl-adc","indication":"AXL-positive solid tumors (Phase 2 development)","status":"phase_2"}]}],"pipeline":[{"name":"BA3071","genericName":"BA3071","slug":"ba3071","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CAB-AXL-ADC","genericName":"CAB-AXL-ADC","slug":"cab-axl-adc","phase":"phase_2","mechanism":"CAB-AXL-ADC is an antibody-drug conjugate that targets AXL-expressing cancer cells and delivers cytotoxic payload upon binding.","indications":["AXL-positive solid tumors (Phase 2 development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNM0p0NzkwcUxacVBNUm1BQktfa2hIaEtGSWd0bFkzV3lSNUhyREdhdC1UVmR3SEMyUWxLTmpJWDgwYW1pODBCOTV1bWlZX3BBY2Vubzh3WU1sZXl5UXpJRWJEa0dBX3V4U0tESDNkWFpqcmVpcDc1TkdscDZLWGpWWjN6dVVnLXUxRmM2U1cwSFdhMFNWX1lLcGk0SFlXcUppREpVLXhnaVBHNkVoWW1qUTB4cExQQ2hv?oc=5","date":"2026-04-01","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Wednesday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNZ01nVTRGNVp0VGRlSXZtdUd4dTEwV1gwUUpYMHN2WWFNMUlPT3gxc29TRmFzbF9DSnZJYU00RUJLdXJWTEJaYzFIaEw0LXpZRFhwaXgtdlJNUVEyWGNBV0ZTNGhnNlJZRHhPYTctMnhYTGF5amxWVGw0TjJTTlU5OXVfNG1uZ2FSb01iQjlkaFFnQ3p2eEFab0xqZ0UtUlhfc2pDa0kydFhzRXJiQkc4NXhxVEVCUQ?oc=5","date":"2026-04-01","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga","headline":"12 Health Care Stocks Moving In Wednesday's Intraday Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNZlAxb3RJREVlaVJ0NXVsZUdfOTJrYTlxbm1jSnZQNGVEd0pwTGplYl9aZ0EwQ2lFS0plREl4TlhVVUFsU0ZMQ2E1b0xnOU1zc3lrVzZuSUpMV00wckpnZURvbUlNTjI5RWtYZUprRlotaHlpcWxKTHFBSXVZSmNhU0lIZEVZbG9MQUtSWlZxX0h5cC1JQ3VHSWttcDFNV2tuQURiWU1lTWY5c3A5R0RQQ2pvbVBHbUdi?oc=5","date":"2026-03-31","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Tuesday's After-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOMThnZWdIUm0tV3hsaW9HTUtuN1p2Y2QxZ1ZQRThvMjBlUlFkYUxKWG1OVmZ4Uk9Nb1dselJRMzBINVdQY3NKSFVwLWNRVW9uQXdhaC1nZmdqRmtPY0Z6NFZwV2lqb0NMNXJldjl2VU1PWVZGQ1ktbUxsODRqb00zRGtwYmF3OTlqU09idU1pSXdSYUhMUzdQcjBzMmR6SzV4OF80VnFLMlRHeFQ4ZHQ0ZjE4NV9LT3cxd1U1VWRKTQ?oc=5","date":"2026-03-06","type":"regulatory","source":"RTTNews","summary":"Weekly Buzz: TBPH Cuts Jobs, ASND Gets FDA Nod, AARD Puts HERO On Hold, ESPR Opens Wallet - RTTNews","headline":"Weekly Buzz: TBPH Cuts Jobs, ASND Gets FDA Nod, AARD Puts HERO On Hold, ESPR Opens Wallet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNTkI2NlVjaGVxaVd1N2I2THZhTHBIRjI4UmVYMkRid3gzenFqRWs0aWhHczBndUpJN1JTX2NrYjgxV3FyNzNzTGI1NjJfVTZCZU1ycW1UeWRYZUpEZFpDTTAtQWM5RXY1NG8xX05obEdwSUdhVS1XR3dJc3VQQUkzaV9YN3ZkU2N6VHYzaE5PRjFkUk5zTTRwdWJURVhtMDlXaEtmblJacDFiU2RBVElVaHdLdGhpTGlzaVg3YXZoVGJUeGVDUlVQM3ppQUdubl9sTjI3MnpvY1dSTW5DMFJ1LVJoTTBocmFKLU53ZVRrek9CNmJadlo4ZWxGT0M?oc=5","date":"2025-12-31","type":"regulatory","source":"Stocktwits","summary":"BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Stocktwits","headline":"BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQb0NMQWk1RVFjbXN2ZmpReVlreXAzSDFkZ3ZaOGpPWkR6dWZkNXdlLVY2NDVmMGpKeDVnT1JBTFN5ZmRrNDRtbTY1VGRHdjFZM3NMZTI0TFZKZy1kazdIMTdxbEhad252TFRxUlFaQWh5VExrbWVkS2l1Qk9DeDVQNnNhTzk3RTAwRUwtVjlpcGFpaFI3VjZiQnlGY0toU3RXQmlfNmpia25GNVVwbTBKcnFEbDVqc1BBSUpUSGpWRG9VbU9reDdXbElFYjNvQVNDdmZNcWhiMmxUc1Rz?oc=5","date":"2025-11-21","type":"pipeline","source":"GlobeNewswire","summary":"BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewswire","headline":"BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOZkhMbXlSek5FSWVmdFdkRkM0RTdiczRNbmFYYWVYQVlUUnhHT0NaYmRlMlhCUnBDS0RLdDlIcUFXRklnVWdIOEE0aWhibTJJRThyaXpmd1VkZnV4OWlzdXVoNGVwV1RKVjNiRWxFNEZRenVtekJYa04waGF4MEFQMm44MFV1dHpyTG56aVlUaDJxV0VTSjZJbm5Tem0wTnNJVWl1SEs4U2U1dGlIT01hX1Y2XzBfNlZ6MmtrT2JkTQ?oc=5","date":"2025-08-13","type":"pipeline","source":"Investing.com","summary":"BioAtla’s SWOT analysis: oncology biotech’s stock faces cash crunch - Investing.com","headline":"BioAtla’s SWOT analysis: oncology biotech’s stock faces cash crunch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOYXM2QTdfbmJwVURFUnBPWXp0REUyblpQNXVXQ1NrY2IwVjdlQzFGaGhmcmZiclZoU0RBQzU0YV9UNmltUVRMX0ZHMEFhU3FzemVjQ1FrcmZ6YllSdmpqM3ROa19fQU1HTzc3SHBBQmFNYXgwaEdPZUNSX3I3RHd0N040MHRiSG95THF6M2FtMDhwQUxSNHhWQWpJNDZvdW9tLU5fT2k3UmQ2MC1kYXZ4ZkVPcC1lMlhHWlhWaEtKOG9HYjFTeFJvdzk2djd1RjVTQUR3LU1sclEwSzJiYUFBN3F3aG1tbXkzckFiT2xzV2VfQjJEY2tNRy02dEp3elFYQmg5Njk0ZThfMEs4eEhYaDhXMFRqVWd2VXdjMXZER0JQVXVVY0VrNGpn?oc=5","date":"2025-07-30","type":"pipeline","source":"PR Newswire","summary":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight - PR Newswire","headline":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technologi","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-21","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're A Bit Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Situation - simplywall.st","headline":"Here's Why We're A Bit Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPR0tVLUt6Mm15Sng0MS1rOVpid21zY2JVZExLYjg1UE05RmJ0ampDUWhyMjRfMktHYVBJcEtTdGZJVjJNTVVOMlhRMlJ5OVF3Z09NTnVMZEJhQmFNTFBnYUI1TnVGQ1NkemdvTGg4a2tQSzFkVHNFVVl0dEdST0g3UkJKMVZaNGd3Wmk3VlIxZDhwMWZzM0V4NjRXaGZaVjQ?oc=5","date":"2025-03-28","type":"deal","source":"Fierce Biotech","summary":"BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody - Fierce Biotech","headline":"BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNX000SkpwVUU0bEt2ZElNVWNsRC1aVU9sVHVIMTBKdmZkNGVjVko1REZLWWV6OExNQU1VSXBjdzBxWW5menlxVW00RVhrZmlia1BrcXRlTHNvZjdXUmZKWlVlU2xzaDBfNTVGY3NUYWxUcU1FRURaQ1FFY243U1NEck9LZTNqY05rb0JKYlRWV3BmREtwWG5WaEVody1VQ0wzUzJWTjUwTzVHc2l2bEF3ODBR?oc=5","date":"2024-10-08","type":"regulatory","source":"Seeking Alpha","summary":"BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy - Seeking Alpha","headline":"BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1EU2lRYXhXSWE2LTVpNE1oQ1ViLUxRVVVqY1lsbktBb1N1R3pYX0ZwWlhPZW1yMU9NdlZBQmw1aHR0TS1NLXNtZXQ4WDlycmlGbllFQWJGQ0drSzFPd2xlRg?oc=5","date":"2020-12-14","type":"pipeline","source":"Market Realist","summary":"Is BioAtla’s IPO Risky or a Good Investment? - Market Realist","headline":"Is BioAtla’s IPO Risky or a Good Investment?","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}